For a specialty drug to succeed commercially, it is not enough to gain FDA approval and secure formulary coverage. The real challenge — one that derails more launches than almost anything else — is getting patients to actually start treatment. That gap between prescription and therapy is what CareTria is designed to close.
When a physician writes a prescription for a specialty medication, it might seem like the hard work is done. The diagnosis has been made, the treatment selected, the prescription written. But for a significant portion of specialty drugs, that moment is not the finish line. It is closer to the starting gun of an entirely separate race.
Between a prescription and a patient actually beginning treatment lies a complex web of benefit verification, prior authorization, copay enrollment, fulfillment logistics, and patient support — any one of which can stall, delay, or permanently prevent therapy from starting. The discipline dedicated to navigating and accelerating that process is called therapy initiation, and it has become one of the most commercially critical functions in biopharma.
Why therapy initiation matters more than ever
The stakes are high on every dimension. For patients, delays in therapy initiation can mean disease progression, worsening symptoms, or permanent harm. For pharma manufacturers, every day between prescription and first dose is lost revenue, a risk of abandonment, and a signal of poor patient experience that can undermine prescriber confidence over time.
Research consistently shows that the longer the gap between prescription and first fill, the lower the probability that a patient ever starts treatment. In specialty pharmacy, abandonment rates at the initiation stage can exceed 30% for some therapy categories — a staggering figure when the medications involved often cost tens of thousands of dollars annually and represent years of clinical development investment.
- 30%+ Specialty Rx abandonment before first fill
- 85% Benefit investigations completed in under 60 seconds
- 800K Provider in CareTria’s network
- 90% Rx-to-therapy conversion rate on CareTria’s Direct-to-Patient-Cash platform
The components of therapy initiation
Therapy initiation is not a single step or a single vendor’s responsibility. It spans several interconnected functions, and the degree to which they are coordinated — or fragmented — directly determines how quickly patients start treatment.
Benefit investigation and verification
Before a specialty drug can be dispensed, someone must determine whether and how a patient’s insurance will cover it. This includes understanding whether the drug falls under the medical benefit, the pharmacy benefit, or both — a distinction that is particularly complex for injectable and infused specialty therapies. Traditional benefit investigation required manual phone calls, faxes, and days of waiting. Modern platforms like CareTria Provider Connect return benefit information in under 60 seconds, directly within the provider’s workflow.
Prior authorization
Most specialty medications require prior authorization — a payer’s formal approval before the drug will be covered. The PA process is notoriously slow and administratively burdensome, and denied PAs are one of the most common reasons patients never start therapy. Electronic prior authorization (ePA) systems automate much of this process, reducing turnaround time from days to hours and improving approval rates through cleaner submissions.
Copay support and patient affordability
Even with insurance, specialty drug out-of-pocket costs can be prohibitive. Manufacturer copay assistance programs, patient assistance programs (PAPs), and bridge programs exist to remove financial barriers — but only if patients are enrolled quickly and efficiently. Delays in copay enrollment frequently cause patients to walk away from therapy before they ever receive it.
Fulfillment routing and pharmacy dispensing
Once coverage and affordability are resolved, the prescription must be routed to the right fulfillment channel — specialty pharmacy, direct-to-patient cash, free goods, or another modality — and dispensed without delay. Multi-modal fulfillment platforms ensure that no single channel bottleneck prevents a patient from receiving therapy.
Patient and provider support
Throughout this process, patients and providers need guidance. Hub services provide a coordination layer — staffed or automated — that manages case status, communicates with providers, and supports patients through the initiation journey.
The integrated approach: why fragmentation fails
For much of the industry’s history, these functions were managed by separate vendors: a hub company here, a specialty pharmacy there, a sampling vendor elsewhere, a 3PL managing logistics. The problem with this fragmented model is compounding latency. Every handoff between vendors is an opportunity for delay, miscommunication, and patient dropout.
The industry has increasingly recognized that an integrated therapy initiation platform — one that connects provider enrollment, benefit verification, prior authorization, pharmacy fulfillment, and logistics in a single coordinated workflow — delivers measurably better outcomes for patients and better economics for manufacturers.
“By combining speed, precision, and scale, CareTria helps patients start therapy sooner while delivering measurable impact for its pharma partners.” — Matt Wolf, Chief Commercial Officer
What to look for in a therapy initiation partner
As pharma manufacturers evaluate their therapy initiation strategy, several capabilities distinguish high-performing partners from average ones:
- Provider network depth and workflow integration — can the platform reach your prescribers where they already work?
- Benefit investigation speed and accuracy — how quickly can you get a complete, reliable benefit picture?
- Multi-modal fulfillment — can the platform route patients to the right dispensing channel automatically?
- Real-time data and analytics — can you see where patients are dropping off and intervene?
- Compliance and quality systems — is the partner equipped to handle specialty drug requirements including GDP, PDMA, and payer-specific rules?
The CareTria model
CareTria was built around the conviction that therapy initiation should be fast, integrated, and measurably effective. Its platform combines a provider network of 800,000+ specialty healthcare providers with embedded automated digital enrollment — returning 85% of benefit investigations in under 60 seconds — connected to multi-modal fulfillment including specialty pharmacy, direct-to-patient cash, samples, free goods, and 3PL distribution.
Real-time data and analytics drive continuous optimization across the product journey, giving pharma partners visibility into every stage of the initiation process and the ability to act on bottlenecks before they cost prescriptions.
Ready to accelerate therapy initiation for your brand? Contact CareTria to learn how an integrated therapy initiation platform can reduce your time-to-first-dose and improve gross-to-net performance. Contact our team today to get started.
